Gothenburg-based BioTech firm VERIGRAFT has been awarded a €1.2 million Eurostars grant to steer the Precision Printed Personalised Tissue Therapies (PREPPER) venture, aiming to develop next-generation 3D-printed arterial grafts.
This initiative seeks to deal with important challenges in present graft know-how, together with restricted availability of human-donated supplies, poor integration, and excessive failure charges. The venture’s success might pave the way in which for preliminary human medical trials and future commercialisation, with potential functions extending past vascular grafts.
“This Eurostars grant is a serious milestone for VERIGRAFT and regenerative drugs. With PREPPER, we’re accelerating the way forward for customized tissue therapies,” stated Dr Raimund Strehl, CTO of VERIGRAFT. “The worldwide vascular graft market is projected to exceed $4 billion by 2026, and PREPPER positions Europe on the forefront of 3D bioprinting and regenerative drugs.”
Based in 2004 by Jan Holgersson, VERIGRAFT is a biotechnology firm rooted within the Karolinska Institute, it has grown to turn out to be a forerunner in industrialised tissue engineering and superior regenerative drugs.
The corporate has a centered R&D pipeline of personalised tissues, concentrating on areas akin to cardiovascular and neuronal illness. VERIGRAFT will commercialise a collection of personalised tissue-engineered grafts on a world market.
“VERIGRAFT affords a singular, breakthrough know-how within the discipline of superior regenerative drugs. The know-how offers the chance to personalize tissues and organs. This can be capable to deliver a paradigm shift in transplantation drugs,” stated Petter Björquist PhD, Chief Govt Officer.
In an ongoing trial, VERIGRAFT has efficiently transplanted their personalised tissue-engineered vein, P-TEV™, into sufferers affected by power venous insufficiency (CVI)—a situation affecting the deep venous system that results in painful swelling and ulceration of the decrease legs. Notably, one affected person in Spain can now stroll unaided for the primary time in years and attend soccer matches.
Collaborating with Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska College Hospital (Sweden), VERIGRAFT will combine superior 3D printing, solution-blown fibre know-how, and personalised tissue engineering. The purpose is to create customised vascular grafts that mimic pure arteries, providing superior sturdiness and seamless integration in comparison with present artificial alternate options.
The PREPPER venture has obtained funding from the Eurostars-3 joint programme, with Co-funding from the European Union’s Horizon Europe analysis and innovation programme. Eurostars is a part of the European Partnership on Progressive SMEs.
By leveraging this grant and collaborative experience, VERIGRAFT goals to revolutionise the sphere of regenerative drugs, offering progressive options for sufferers requiring arterial grafts and positioning Europe as a pacesetter in 3D bioprinting know-how.
